Login to Your Account

Earnings Roundup

Gilead's HIV Franchise Solid; HCV, Quad to Round out 2012

By Jennifer Boggs
Managing Editor

Monday, April 30, 2012
Gilead Sciences Inc. beat revenue estimates for the first quarter, but missed earnings-per-share consensus by 2 cents, as it reported solid sales for its antiviral franchise, including impressive uptake of recently launched triple-drug, single-tablet HIV drug Complera.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription